Regulation & law · 19/10/1995

Boehringer Ingelheim Pharmaceuticals Inc. Files Request for FDA Approval to Export Atrovent Nasal Spray to Canada

The US Food and Drug Administration (FDA) has received a request from Boehringer Ingelheim Pharmaceuticals Inc. to export the prescription medication Atrovent (Ipratropium Bromide) Nasal Spray 0.03% in 10 milliliter and 30 milliliter volumes to Canada.